Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines (Q47784884)

5 February 2018

title

Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines (English)

1 reference

5 February 2018

1 reference

2

1 reference

5 February 2018

author name string

Marcus V Cronauer

1

1 reference

5 February 2018

Tatjana Burchardt

3

1 reference

5 February 2018

Rolf Ackermann

4

1 reference

5 February 2018

Martin Burchardt

5

1 reference

5 February 2018

language of work or name

English

0 references

publication date

1 April 2004

1 reference

5 February 2018

published in

Oncogene

1 reference

5 February 2018

volume

23

1 reference

5 February 2018

issue

20

1 reference

5 February 2018

page(s)

3541-3549

1 reference

5 February 2018

https://scigraph.springernature.com/pub.10.1038/sj.onc.1207346

exact match

0 references

cites work

Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207346

Inactivation of p21WAF1 sensitizes cells to apoptosis via an increase of both p14ARF and p53 levels and an alteration of the Bax/Bcl-2 ratio.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207346

P53 mediates the apoptotic response to GTP depletion after renal ischemia-reperfusion: protective role of a p53 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207346

p53 inhibitor pifithrin alpha can suppress heat shock and glucocorticoid signaling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207346

p53 represses androgen-induced transactivation of prostate-specific antigen by disrupting hAR amino- to carboxyl-terminal interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207346

Modulation of the transcriptional activity of thyroid hormone receptors by the tumor suppressor p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207346

Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207346

7 January 2021

Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207346

7 January 2021

Reduction of wild type p53 function confers a hormone resistant phenotype on LNCaP prostate cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207346

7 January 2021

p53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207346

7 January 2021

p53 oncogene mutations in three human prostate cancer cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207346

7 January 2021

Androgen-mediated resistance to apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207346

7 January 2021

A reliable system for the culture of human prostatic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207346

7 January 2021

Androgen receptor protein is down-regulated by basic fibroblast growth factor in prostate cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207346

7 January 2021

Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207346

7 January 2021

Expression of prostate specific antigen (PSA) is negatively regulated by p53.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207346

7 January 2021

Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207346

7 January 2021

A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207346

7 January 2021

Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207346

7 January 2021

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207346

7 January 2021

p53 protein accumulation and gene mutation in the progression of human prostate carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207346

7 January 2021

Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207346

7 January 2021

A new human prostate carcinoma cell line, 22Rv1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207346

7 January 2021

Recombinant adenovirus vector expressing wild-type p53 is a potent inhibitor of prostate cancer cell proliferation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207346

7 January 2021

The tumor suppressor p53 is a negative regulator of estrogen receptor signaling pathways

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207346

7 January 2021

Modulation of hormone-dependent transcriptional activity of the glucocorticoid receptor by the tumor suppressor p53

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207346

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1207346

1 reference

5 February 2018

PubMed ID

15077179

1 reference

5 February 2018